Advanced Malignant Solid Neoplasm Clinical Trials in Boston, Massachusetts

4 studies are recruiting for advanced malignant solid neoplasm in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

   This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) …

   Stage

   Phase 2

   Ages

   Any age

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   482 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564377 on ClinicalTrials.gov

2. Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

   This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   27 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06311214 on ClinicalTrials.gov

3. Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

   This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   7 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05687136 on ClinicalTrials.gov

4. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

   This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN0…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   4 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05111561 on ClinicalTrials.gov